trifluridine/tipiracil (Lonsurf) -

trifluridine/tipiracil (Lonsurf)
Information type: Guidance
Source: Scottish Medicines Consortium
Specialities: Cancers | Gastrointestinal disorders
Summary
The SMC has accepted for use within NHS Scotland, Lonsurf for metastatic colorectal cancer who have been previously treated with, or are not considered suitable for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, VEG-F inhibitors, and anti-EGFR agents.
UKMi comment
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of trifluridine/tipiracil (Lonsurf).

The National Institute for Health and Care Excellence (NICE) has also previously similarly approved the use of trifluridine–tipiracil for previously treated metastatic colorectal cancer (Aug 2016).
Related links: Link to NICE TA 405